i-MICST^TM

Magnetic cell purification and gene delivery in one integrated system

i-MICST™ Technology (Integrated Magnetic Immuno-Cell Sorting and Transfection / Transduction) is a new platform that allows to genetically modifying cells directly on magnetic cell purification columns.

This technology combines cell isolation and genetic modification
in one simple and reliable integrated system and results in efficient and selective gene delivery to target cells.
i-MICST™ Technology allows you to reduce cell manipulation steps and save time and material. 

• Isolation and genetic modification in one reliable integrated system

• Highly efficient

• Rapid, simple and ready to use

• Suitable for all cells 

i-MICST™ Technology principle

How it works

• i-MICST™ Technology requires:

- Magnetic cell separation systems (not provided by OZ Biosciences)
- Viro-MICST™ reagent for capturing virus and infecting cells within the magnetic cell
purification column.
This reagent is a new specific magnetic nanoparticles formulation issued from our Magnetofection^TM technology.

Viro-MICST was developed in association with MACS^® technology * from Miltenyi Biotec.
Results and demonstration were performed on MS and LS columns with MACS^® separators
and the cell separation reagents according to MACS^® cell separation protocol.

• Rapid, simple and ready-to-use

I / Cell preparation and Pre-enrichment of the target cells

1. Magnetically label your cells following the manufacturer's instructions
2. If cells to be purified < 50% of total cells, and/or cell purity< 90%, proceed to a
   pre-enrichment step on non-modified column(s)   

II/ Viral i-MICST™ procedure

Applications and Results 

High level of target cell transduction during purification Significant improvement over the standard method

Fig.1: Viro-MICST™ increases the transduction efficiency of Primary Blood Mononuclear Cells during purification step onto a modified cell sorting column. Human PBMC (extracted from whole blood) were labeled with either CD45, CD2 or CD15 microbeads then each condition were loaded into: i)      one unmodified LS column, and selected cells were then infected using standard lentiviral protocol with a MOI of 0.5 (standard infection) or ii)     one unmodified LS column followed by a LS column modified with Viro-MICST/ LV. eGFP complexes formulated at a MOI of 0.5 with 6.5 µL of Viro-MICST per 10e6 VP. Infection efficiency was measured by flow cytometry [*].    More results

*MACS^® is a registered trademark owned by Miltenyi Biotec GmbH and the use of MACS^® column
is proprietary and patented technology.For any further licensed of MACS^® system,
please contact Miltenyi .